# New clinical trials in Armenia: 20 since Nov 2024

Updated August 7, 2026.

20 clinical studies with a site in Armenia were first posted on ClinicalTrials.gov from November 13, 2024 to August 7, 2026; 13 have an industry sponsor and 11 are recruiting or about to. The newest, NCT07753083, was posted on August 7, 2026: Structured Graphic Motor Therapy in Pediatric CP (Armenian State Institute of Physical Culture and Sport).

## The full list

New clinical trials with a site in Armenia: 20 rows for $5, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/country/armenia

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 20
- Industry sponsored: 13
- Recruiting or not yet: 11
- Latest posted: August 7, 2026

## Newest trials

The newest 20 of 20, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 7, 2026 | NCT07753083 | Structured Graphic Motor Therapy in Pediatric CP | Armenian State Institute of Physical Culture and Sport | Not applicable | Completed | Cerebral Palsy (CP) | 12 | Armenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753083) |
| June 8, 2026 | NCT07632014 | CAYA Cancer Prospective Cohort Study | Resonance, Inc. | Observational | Recruiting | Cancer, Pediatric Cancer, Lymphoblastic Lymphoma (LBL), Acute Lymphoblastic Leukemia (ALL) | 6,000 | Armenia, Egypt, El Salvador, Guatemala, Honduras | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07632014) |
| May 19, 2026 | NCT07595016 | Clinical Validation of the Blood Pressure Measuring Device Withings BPM Pro 2 in Pregnancy and Pre-Eclampsia | Withings | Not applicable | Recruiting | Hypertension, Pre-eclampsia | 45 | Armenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07595016) |
| May 13, 2026 | NCT07583446 | Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock | Seismic Pharmaceuticals Operations LLC | Phase 2/3 | Recruiting | Cardiogenic Shock | 600 | Armenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583446) |
| January 8, 2026 | NCT07325097 | PVEK Corneal Implant For Treatment of Corneal Edema | Precise Bio | Phase 1 | Recruiting | Corneal Edema, Fuchs' Endothelial Dystrophy, Pseudophakic Bullous Keratopathy, Corneal Endothelial Dysfunction | 15 | Armenia, Israel | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07325097) |
| November 24, 2025 | NCT07246213 | CAYA Cancer Retrospective Cohort Study | Resonance, Inc. | Observational | Recruiting | Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Young Adult Cancer, Adolescent Cancer, Childhood Cancers, Acute... | 18,000 | Armenia, Egypt, El Salvador, Guatemala, Honduras, Tanzania | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07246213) |
| September 5, 2025 | NCT07156916 | A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin... | Berlin-Chemie AG Menarini Group | Phase 1 | Recruiting | Healthy Volunteer Male Subjects | 46 | Armenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07156916) |
| August 28, 2025 | NCT07146711 | A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tabsulosine 0.4 mg... | Berlin-Chemie AG Menarini Group | Phase 1 | Active not recruiting | Healthy Adult Males Volunteers | 33 | Armenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07146711) |
| July 29, 2025 | NCT07091669 | A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin 0.4 mg... | Berlin-Chemie AG Menarini Group | Phase 1 | Active not recruiting | Healthy Volunteers, Male | 46 | Armenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07091669) |
| July 23, 2025 | NCT07081347 | This Follow-up Extension Study is Aimed to Monitor the Long-term IOP-lowering Performance/Efficacy and Safety of the MINT® Procedure in... | Sanoculis Ltd | Not applicable | Completed | Glaucoma, Ocular Hypertension, Open-Angle Glaucoma | 47 | Armenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07081347) |
| July 22, 2025 | NCT07078331 | Safety and Performance, and Dose, of OsteoAdapt DE in Localized Alveolar Ridge Augmentations | Theradaptive, Inc | Phase 1/2 | Active not recruiting | Tooth Extraction Site Healing, Ridge Augmentation, Bone Graft | 45 | Armenia, Israel | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07078331) |
| July 4, 2025 | NCT07051174 | The Minimally Invasive Micro Sclerostomy (MIMS®) System is Intended for the Reduction of Elevated Intraocular Pressure (IOP): The Minimally... | Sanoculis Ltd | Not applicable | Completed | Glaucoma | 88 | Armenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07051174) |
| June 3, 2025 | NCT07001852 | EnDOvascular Therapy for Late WiNdow IschEmic Stroke Patients Selected bY AutoMatic Plain ComputErized Tomography | Santiago Ortega Gutierrez | Not applicable | Recruiting | Stroke Acute | 500 | Armenia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07001852) |
| May 14, 2025 | NCT06970899 | Initial Feasibility Study of the CycloPE® Device | PATH EX, Inc. | Not applicable | Active not recruiting | Sepsis, Infection, Bacteremia Sepsis, Systemic Inflammatory Response Syndrome (SIRS) | 15 | Armenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06970899) |
| May 5, 2025 | NCT06957847 | Clinical Validation of the Blood Pressure Measuring Device Withings BPM Pro 2 (WIHYP-GP) | Withings | Not applicable | Completed | Hypertension | 89 | Armenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06957847) |
| March 7, 2025 | NCT06864351 | Prospective Evaluation of OptiThyDose | University Children's Hospital Basel | Not applicable | Recruiting | Thyroid Diseases, Congenital Hypothyroidism, Graves Disease | 150 | Armenia, France, Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06864351) |
| February 18, 2025 | NCT06832722 | A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. | 4TEEN4 Pharmaceuticals GmbH | Phase 1/2 | Recruiting | Shock, Cardiogenic | 90 | Armenia, Belgium, Czechia, France, Germany, Netherlands, Poland, Serbia, Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06832722) |
| December 27, 2024 | NCT06748924 | Chronic Coronary Syndrome Snapshot Study | European Society of Cardiology | Observational | Recruiting | Chronic Coronary Syndrome | 4,000 | Armenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06748924) |
| December 4, 2024 | NCT06715579 | Cardiac Angiosarcoma International Registry | Immune Oncology Research Institute | Observational | Recruiting | Cardiac Angiosarcoma | 500 | Armenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06715579) |
| November 13, 2024 | NCT06687369 | A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in... | mAbxience Research S.L. | Phase 3 | Active not recruiting | Non Squamous Non Small Cell Lung Cancer | 726 | Armenia, Bosnia and Herzegovina, Brazil, Georgia, Greece, Italy, Japan, Jordan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06687369) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Berlin-Chemie AG Menarini Group | 3 | September 5, 2025 |
| Resonance, Inc. | 2 | June 8, 2026 |
| Withings | 2 | May 19, 2026 |
| Sanoculis Ltd | 2 | July 23, 2025 |
| Armenian State Institute of Physical Culture and Sport | 1 | August 7, 2026 |
| Seismic Pharmaceuticals Operations LLC | 1 | May 13, 2026 |
| Precise Bio | 1 | January 8, 2026 |
| Theradaptive, Inc | 1 | July 22, 2025 |
| Santiago Ortega Gutierrez | 1 | June 3, 2025 |
| PATH EX, Inc. | 1 | May 14, 2025 |
| University Children's Hospital Basel | 1 | March 7, 2025 |
| 4TEEN4 Pharmaceuticals GmbH | 1 | February 18, 2025 |
| European Society of Cardiology | 1 | December 27, 2024 |
| Immune Oncology Research Institute | 1 | December 4, 2024 |
| mAbxience Research S.L. | 1 | November 13, 2024 |

## Conditions

| Condition group | New trials | Latest |
| --- | --- | --- |
| [Neoplasms](https://specstream.ai/data/clinical-trials/condition/neoplasms) | 2 | June 8, 2026 |
| [Precursor Cell Lymphoblastic Leukemia-Lymphoma](https://specstream.ai/data/clinical-trials/condition/precursor-cell-lymphoblastic-leukemia-lymphoma) | 2 | June 8, 2026 |
| [Hypertension](https://specstream.ai/data/clinical-trials/condition/hypertension) | 2 | May 19, 2026 |
| Shock, Cardiogenic | 2 | May 13, 2026 |
| [Glaucoma](https://specstream.ai/data/clinical-trials/condition/glaucoma) | 2 | July 23, 2025 |
| [Cerebral Palsy](https://specstream.ai/data/clinical-trials/condition/cerebral-palsy) | 1 | August 7, 2026 |
| [Pre-Eclampsia](https://specstream.ai/data/clinical-trials/condition/pre-eclampsia) | 1 | May 19, 2026 |
| Corneal Edema | 1 | January 8, 2026 |
| Fuchs' Endothelial Dystrophy | 1 | January 8, 2026 |
| Ocular Hypertension | 1 | July 23, 2025 |
| Glaucoma, Open-Angle | 1 | July 23, 2025 |
| [Stroke](https://specstream.ai/data/clinical-trials/condition/stroke) | 1 | June 3, 2025 |
| [Ischemic Stroke](https://specstream.ai/data/clinical-trials/condition/ischemic-stroke) | 1 | June 3, 2025 |
| [Sepsis](https://specstream.ai/data/clinical-trials/condition/sepsis) | 1 | May 14, 2025 |
| [Infections](https://specstream.ai/data/clinical-trials/condition/infections) | 1 | May 14, 2025 |
| Systemic Inflammatory Response Syndrome | 1 | May 14, 2025 |
| Thyroid Diseases | 1 | March 7, 2025 |
| Congenital Hypothyroidism | 1 | March 7, 2025 |
| Graves Disease | 1 | March 7, 2025 |
| Hemangiosarcoma | 1 | December 4, 2024 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 8 | August 7, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 4 | June 8, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 4 | January 8, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 2 | July 22, 2025 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 1 | May 13, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 1 | November 13, 2024 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).